Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,825
+6.05%
|
-
|
|
Dec 03
2021
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
100
-4.19%
|
$22,300
$223.92 P/Share
|
|
Dec 03
2021
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
339
+12.61%
|
$75,597
$223.92 P/Share
|
|
Dec 02
2021
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-12.98%
|
$37,620
$228.52 P/Share
|
|
Dec 02
2021
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
372
+22.64%
|
$84,816
$228.52 P/Share
|
|
Sep 01
2021
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,582
-36.09%
|
$872,716
$338.24 P/Share
|
|
Sep 01
2021
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,005
+45.3%
|
$2,029,690
$338.24 P/Share
|
|
Aug 09
2021
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
523
-1.26%
|
-
|
|
Jul 01
2021
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
74
-7.83%
|
$25,752
$348.92 P/Share
|
|
Jul 01
2021
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
251
+20.99%
|
$87,348
$348.92 P/Share
|
|
Jul 01
2021
|
William D /Ca/ Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
Jul 01
2021
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+17.25%
|
-
|
|
Jul 01
2021
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+21.56%
|
-
|
|
Jul 01
2021
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,275
+13.99%
|
-
|
|
Jul 01
2021
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
Jul 01
2021
|
Nancy Leaming Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+5.33%
|
-
|
|
Jul 01
2021
|
Richard Mulligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+5.34%
|
-
|
|
Jul 01
2021
|
Brian S Posner Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+8.66%
|
-
|
|
Jul 01
2021
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+4.16%
|
-
|
|
Jul 01
2021
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+4.33%
|
-
|
|
Jul 01
2021
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+3.42%
|
-
|
|
Jul 01
2021
|
Alexander J Denner Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+5.34%
|
-
|
|
Jun 07
2021
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Open market or private sale
|
Direct |
3,087
-51.4%
|
$1,358,280
$440.0 P/Share
|
|
Jun 07
2021
|
Alfred Sandrock Head of Research & Development |
SELL
Open market or private sale
|
Direct |
7,672
-43.0%
|
$3,375,680
$440.0 P/Share
|
|
Jun 04
2021
|
Brian S Posner Director |
SELL
Open market or private sale
|
Direct |
360
-4.64%
|
$98,640
$274.17 P/Share
|
|
Feb 12
2021
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,896
-2.32%
|
$1,083,088
$278.03 P/Share
|
|
Feb 12
2021
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,355
+3.34%
|
-
|
|
Feb 12
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-4.33%
|
$198,770
$278.03 P/Share
|
|
Feb 12
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,573
+10.76%
|
-
|
|
Feb 12
2021
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,182
-6.72%
|
$606,596
$278.03 P/Share
|
|
Feb 12
2021
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,923
+10.58%
|
-
|
|
Feb 12
2021
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
940
-7.01%
|
$261,320
$278.03 P/Share
|
|
Feb 12
2021
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
3,156
+20.65%
|
-
|
|
Feb 12
2021
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
115
-8.47%
|
$31,970
$278.03 P/Share
|
|
Feb 12
2021
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
333
+21.38%
|
-
|
|
Feb 12
2021
|
Alfred Sandrock Head of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
3,510
-4.88%
|
$975,780
$278.03 P/Share
|
|
Feb 12
2021
|
Alfred Sandrock Head of Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
4,454
+7.56%
|
-
|
|
Feb 12
2021
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,473
-6.67%
|
$4,023,494
$278.03 P/Share
|
|
Feb 12
2021
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,289
+9.06%
|
-
|
|
Feb 09
2021
|
Jesus B Mantas Director |
BUY
Open market or private purchase
|
Direct |
898
+23.38%
|
$239,766
$267.0 P/Share
|
|
Jan 27
2021
|
Michel Vounatsos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,343
+24.21%
|
-
|
|
Jan 27
2021
|
Alfred Sandrock Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,728
+18.17%
|
-
|
|
Jan 27
2021
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,558
+26.08%
|
-
|
|
Jan 27
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
818
+19.19%
|
-
|
|
Jan 27
2021
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,545
+9.95%
|
-
|
|
Dec 03
2020
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22
-5.57%
|
$5,368
$244.09 P/Share
|
|
Dec 03
2020
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74
+15.78%
|
-
|
|
Dec 01
2020
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
562
-7.17%
|
$136,566
$243.16 P/Share
|
|
Dec 01
2020
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
481
+10.72%
|
-
|
|
Nov 30
2020
|
Michel Vounatsos Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,100
+8.18%
|
$747,100
$241.31 P/Share
|